These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Rosenthal A; Mesa RA Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055 [TBL] [Abstract][Full Text] [Related]
51. Guidelines for the management of myeloproliferative neoplasms. Choi CW; Bang SM; Jang S; Jung CW; Kim HJ; Kim HY; Kim SJ; Kim YK; Park J; Won JH Korean J Intern Med; 2015 Nov; 30(6):771-88. PubMed ID: 26552452 [TBL] [Abstract][Full Text] [Related]
52. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. Choong ML; Pecquet C; Pendharkar V; Diaconu CC; Yong JW; Tai SJ; Wang SF; Defour JP; Sangthongpitag K; Villeval JL; Vainchenker W; Constantinescu SN; Lee MA J Cell Mol Med; 2013 Nov; 17(11):1397-409. PubMed ID: 24251790 [TBL] [Abstract][Full Text] [Related]
53. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]